Preliminary unaudited revenue for the fourth quarter and full year 2022 is anticipated to be in the range of $49.1 to $49.6 million and $141.2 to $141.7 million, respectively, representing an increase in the range of 47% to 48% and 50% over the same periods last year, respectively. The full year growth rate range benefited from the Company’s strategic investments into its direct sales channel, research and development, and direct-to-consumer programs. For the full year 2022, Treace previously provided revenue guidance to be in the range of $135 million to $138 million, which represented approximately 43% to 46% growth over the Company’s 2021 revenue. "Preliminary 2022 revenue growth of 50% and fourth quarter revenue growth of 47% to 48% demonstrate the underlying strength and effectiveness of our strategic investments into our direct sales channel, direct-to-consumer programs, and targeted R&D initiatives. With our focus to advance the standard of care in the surgical management of bunions and related midfoot deformities, we believe we remain well positioned to drive market penetration of our Lapiplasty(R) and Adductoplasty(R) systems as well as other complementary product innovations," said John T. Treace, CEO, Founder and Board Member of Treace.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TMCI:
- Treace to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
- Treace Medical granted two bone positioning device patents from USPTO
- Treace Medical Announces Expansion of Its Global IP Portfolio with the Grant of Two New U.S. Patents
- Treace Medical announces bunion treatment SpeedPlate gets 510k clearance
- Treace Announces First Patient Treated in MTA3D™ Adductoplasty® Clinical Study